Aurora Spine マネジメント

マネジメント基準チェック /34

Aurora Spineの CEO はTrent Northcuttで、 Feb2012年に任命され、の在任期間は 12.83年です。の年間総報酬は$ 175.23Kで、 77.8%給与と22.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.8%を直接所有しており、その価値はCA$ 2.24M 。経営陣と取締役会の平均在任期間はそれぞれ11.9年と11.4年です。

主要情報

Trent Northcutt

最高経営責任者

US$175.2k

報酬総額

CEO給与比率	77.8%
CEO在任期間	12.8yrs
CEOの所有権	6.8%
経営陣の平均在職期間	11.9yrs
取締役会の平均在任期間	11.4yrs

経営陣の近況

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Recent updates

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Jun 19

Is Aurora Spine (CVE:ASG) A Risky Investment?

May 29

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

Mar 19

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Oct 15

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aug 11

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

May 01

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Dec 22

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aug 23

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

May 04

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Dec 23

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Jun 11

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

Feb 26

Is Aurora Spine (CVE:ASG) A Risky Investment?

Nov 19

CEO報酬分析

Aurora Spine の収益と比較して、Trent Northcutt の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$636k
Jun 30 2024	n/a	n/a	-US$956k
Mar 31 2024	n/a	n/a	-US$1m
Dec 31 2023	US$175k	US$136k	-US$2m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$123k	US$106k	-US$2m
Sep 30 2022	n/a	n/a	-US$2m
Jun 30 2022	n/a	n/a	-US$2m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$127k	US$111k	-US$2m
Sep 30 2021	n/a	n/a	-US$1m
Jun 30 2021	n/a	n/a	-US$793k
Mar 31 2021	n/a	n/a	-US$58k
Dec 31 2020	US$143k	US$131k	-US$232k
Sep 30 2020	n/a	n/a	-US$777k
Jun 30 2020	n/a	n/a	-US$2m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$143k	US$131k	-US$1m
Sep 30 2019	n/a	n/a	-US$756k
Jun 30 2019	n/a	n/a	-US$199k
Mar 31 2019	n/a	n/a	-US$114k
Dec 31 2018	US$157k	US$125k	-US$68k
Sep 30 2018	n/a	n/a	-US$877k
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$137k	US$125k	-US$2m

報酬と市場: Trentの総報酬 ($USD 175.23K ) は、 Canadian市場 ($USD 164.07K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Trentの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Trent Northcutt (57 yo)

12.8yrs

在職期間

US$175,227

報酬

Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Trent Northcutt	Founder	12.8yrs	US$175.23k	6.8% CA$ 2.2m
Chad Clouse	Chief Financial Officer	4.4yrs	US$168.37k	0.0077% CA$ 2.6k
Laszlo Garamszegi	CTO & Founder	11.9yrs	US$151.07k	データなし
David Meyer	VP, Chief Legal Officer & Secretary	no data	US$143.07k	データなし
Matthew Goldstone	Chief Commercial Officer	no data	データなし	データなし

11.9yrs

平均在職期間

経験豊富な経営陣: ASGの経営陣は経験豊富で経験豊富です（平均在職期間は11.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Trent Northcutt	Founder	11.4yrs	US$175.23k	6.8% CA$ 2.2m
David Rosenkrantz	Independent Chairman	11.4yrs	データなし	15.87% CA$ 5.2m
Tracy Graf	Independent Director	11.4yrs	データなし	0.54% CA$ 178.5k
Joseph MacLellan	Independent Director	11.4yrs	データなし	0.18% CA$ 60.8k
James Snow	Independent Director	11.4yrs	データなし	0.77% CA$ 254.7k
Michael Seid	Independent Director	11.4yrs	データなし	0.13% CA$ 41.2k

11.4yrs

平均在職期間

59.5yo

平均年齢

経験豊富なボード: ASGの取締役会は経験豊富で経験豊富です ( 11.4年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/22 21:26
終値	2024/12/20 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Aurora Spine Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。1

アナリスト	機関
Neal Gilmer	Clarus Securities Inc.

Aurora Spine マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

Independent Director recently sold CA$135k worth of stock

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Independent Chairman exercised options to buy CA$355k worth of stock.

Recent updates

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)

New 90-day high: CA$0.53

Aurora Spine Corporation(TSXV:ASG) dropped from S&P/TSX Venture Composite Index

New 90-day high: CA$0.44

New 90-day high: CA$0.38

マネジメント基準チェック /34